ProCE Banner Activity

The Use of Antibody–Drug Conjugates as Novel Therapies for Patients With Advanced NSCLC: Advanced Practice Professional Considerations

Clinical Thought

Commentary from 2 advanced practice professionals discussing antibody–drug conjugates (ADCs) as novel therapeutic options for patients with advanced NSCLC, including their thoughts on determining patient eligibility for ADCs at disease recurrence, available clinical data related to the use of ADCs, and helpful resources to share with your patients.

Released: September 27, 2024

Expiration: September 26, 2025

Share

Faculty

Blanca Ledezma

Blanca Ledezma, MSN, NP-AOCNP

Nurse Practitioner III
Division of Hematology/Oncology
UCLA Santa Monica
Santa Monica, California

Denise Rouse

Denise Rouse, MS, PA-C

Physician Assistant
Thoracic Medical Oncology
Department of Medicine, Section of Hematology/Oncology
The University of Chicago Medicine & Biological Sciences
Chicago, Illinois

Provided by

Provided by Partners for Advancing Clinical Education, in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Faculty Disclosure

Primary Author

Blanca Ledezma, MSN, NP-AOCNP

Nurse Practitioner III
Division of Hematology/Oncology
UCLA Santa Monica
Santa Monica, California

Blanca Ledezma, MSN, NP-AOCNP: consultant/advisor/speaker: AstraZeneca, Lilly.

Denise Rouse, MS, PA-C

Physician Assistant
Thoracic Medical Oncology
Department of Medicine, Section of Hematology/Oncology
The University of Chicago Medicine & Biological Sciences
Chicago, Illinois

Denise Rouse, MS, PA-C: consultant/advisor/speaker: Bristol Myers Squibb, Catalyst, Johnson & Johnson, Puma.